Browse
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Search for other papers by Victoria Byrd in
Google Scholar
PubMed
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Search for other papers by Ted Getz in
Google Scholar
PubMed
Search for other papers by Roshan Padmanabhan in
Google Scholar
PubMed
Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for other papers by Hans Arora in
Google Scholar
PubMed
Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Search for other papers by Charis Eng in
Google Scholar
PubMed
Germline PTEN mutations defining PTEN hamartoma tumor syndrome (PHTS) confer heritable predisposition to breast, endometrial, thyroid and other cancers with known age-related risks, but it remains impossible to predict if any individual will develop cancer. In the general population, gut microbial dysbiosis has been linked to cancer, yet is unclear whether these are associated in PHTS patients. In this pilot study, we aimed to characterize microbial composition of stool, urine, and oral wash from 32 PTEN mutation-positive individuals using 16S rRNA gene sequencing. PCoA revealed clustering of the fecal microbiome by cancer history (P = 0.03, R 2 = 0.04). Fecal samples from PHTS cancer patients had relatively more abundant operational taxonomic units (OTUs) from family Rikenellaceae and unclassified members of Clostridia compared to those from non-cancer patients, whereas families Peptostreptococcaceae, Enterobacteriaceae, and Bifidobacteriaceae represented relatively more abundant OTUs among fecal samples from PHTS non-cancer patients. Functional metagenomic prediction revealed enrichment of the folate biosynthesis, genetic information processing and cell growth and death pathways among fecal samples from PHTS cancer patients compared to non-cancer patients. We found no major shifts in overall diversity and no clustering by cancer history among oral wash or urine samples. Our observations suggest the utility of an expanded study to interrogate gut dysbiosis as a potential cancer risk modifier in PHTS patients.
Search for other papers by Tobias Hofving in
Google Scholar
PubMed
Search for other papers by Yvonne Arvidsson in
Google Scholar
PubMed
Search for other papers by Bilal Almobarak in
Google Scholar
PubMed
Search for other papers by Linda Inge in
Google Scholar
PubMed
Search for other papers by Roswitha Pfragner in
Google Scholar
PubMed
Search for other papers by Marta Persson in
Google Scholar
PubMed
Search for other papers by Göran Stenman in
Google Scholar
PubMed
Search for other papers by Erik Kristiansson in
Google Scholar
PubMed
Search for other papers by Viktor Johanson in
Google Scholar
PubMed
Search for other papers by Ola Nilsson in
Google Scholar
PubMed
Experimental models of neuroendocrine tumour disease are scarce, and no comprehensive characterisation of existing gastroenteropancreatic neuroendocrine tumour (GEPNET) cell lines has been reported. In this study, we aimed to define the molecular characteristics and therapeutic sensitivity of these cell lines. We therefore performed immunophenotyping, copy number profiling, whole-exome sequencing and a large-scale inhibitor screening of seven GEPNET cell lines. Four cell lines, GOT1, P-STS, BON-1 and QGP-1, displayed a neuroendocrine phenotype while three others, KRJ-I, L-STS and H-STS, did not. Instead, these three cell lines were identified as lymphoblastoid. Characterisation of remaining authentic GEPNET cell lines by copy number profiling showed that GOT1, among other chromosomal alterations, harboured losses on chromosome 18 encompassing the SMAD4 gene, while P-STS had a loss on 11q. BON-1 had a homozygous loss of CDKN2A and CDKN2B, and QGP-1 harboured amplifications of MDM2 and HMGA2. Whole-exome sequencing revealed both disease-characteristic mutations (e.g. ATRX mutation in QGP-1) and, for patient tumours, rare genetic events (e.g. TP53 mutation in P-STS, BON-1 and QGP-1). A large-scale inhibitor screening showed that cell lines from pancreatic NETs to a greater extent, when compared to small intestinal NETs, were sensitive to inhibitors of MEK. Similarly, neuroendocrine NET cells originating from the small intestine were considerably more sensitive to a group of HDAC inhibitors. Taken together, our results provide a comprehensive characterisation of GEPNET cell lines, demonstrate their relevance as neuroendocrine tumour models and explore their therapeutic sensitivity to a broad range of inhibitors.
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
Search for other papers by David J Gross in
Google Scholar
PubMed
Department of Endocrinology, Royal Victoria Infirmary, Newcastle Upon Tyne, UK
Search for other papers by Marta Benavent in
Google Scholar
PubMed
Search for other papers by Petros Perros in
Google Scholar
PubMed
Search for other papers by Raj Srirajaskanthan in
Google Scholar
PubMed
Search for other papers by Richard R P Warner in
Google Scholar
PubMed
Search for other papers by Matthew H Kulke in
Google Scholar
PubMed
Search for other papers by Lowell B Anthony in
Google Scholar
PubMed
Search for other papers by Pamela L Kunz in
Google Scholar
PubMed
Search for other papers by Dieter Hörsch in
Google Scholar
PubMed
Search for other papers by Martin O Weickert in
Google Scholar
PubMed
Search for other papers by Pablo Lapuerta in
Google Scholar
PubMed
Search for other papers by Wenjun Jiang in
Google Scholar
PubMed
Search for other papers by Kenneth Kassler-Taub in
Google Scholar
PubMed
Search for other papers by Suman Wason in
Google Scholar
PubMed
Search for other papers by Rosanna Fleming in
Google Scholar
PubMed
Search for other papers by Douglas Fleming in
Google Scholar
PubMed
Search for other papers by Rocio Garcia-Carbonero in
Google Scholar
PubMed
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid (u5-HIAA)) with <4 BMs/day on SSAs (or ≥1 symptom or ≥4 BMs/day if not on SSAs) during a 12-week double-blind treatment period followed by a 36-week open-label extension (OLE). The primary safety and efficacy endpoints were incidence of treatment-emergent adverse events (TEAEs) and percent change from baseline in 24-h u5-HIAA at week 12. Patients (N = 76) were randomly assigned (1:1:1) to receive placebo or telotristat ethyl 250 mg or 500 mg 3 times per day (tid); 67 continued receiving telotristat ethyl 500 mg tid during the OLE. Through week 12, TEAEs were generally mild to moderate in severity; 5 (placebo), 1 (telotristat ethyl 250 mg) and 3 (telotristat ethyl 500 mg) patients experienced serious events, and the rate of TEAEs in the OLE was comparable. At week 12, significant reductions in u5-HIAA from baseline were observed, with Hodges–Lehmann estimators of median treatment differences from placebo of −54.0% (95% confidence limits, −85.0%, −25.1%, P < 0.001) and −89.7% (95% confidence limits, −113.1%, −63.9%, P < 0.001) for telotristat ethyl 250 mg and 500 mg. These results support the safety and efficacy of telotristat ethyl when added to SSAs in patients with CS diarrhea (ClinicalTrials.gov identifier: Nbib2063659).
Organisation for Oncology and Translational Research, Hong Kong SAR, China
UNIMED Medical Institute, Hong Kong SAR, China
Search for other papers by Louis W C Chow in
Google Scholar
PubMed
Search for other papers by Satoshi Morita in
Google Scholar
PubMed
Search for other papers by Christopher Y C Chow in
Google Scholar
PubMed
Search for other papers by Wai-Kuen Ng in
Google Scholar
PubMed
Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
Search for other papers by Masakazu Toi in
Google Scholar
PubMed
The purpose of the study was to test the efficacy of neoadjuvant palbociclib therapy and to evaluate its impact on cell cycle arrest and changes in EndoPredict (EP) scores before and after treatment. Postmenopausal women with histologically proven ER+ve, HER2−ve invasive breast cancer, 2 cm or greater, were enrolled in an open-label, single-arm study. Twenty eligible patients were given letrozole 2.5 mg per day together with palbociclib 125 mg per day for 3 out of 4 weeks in repeated cycles for 16 weeks (4 cycles) before surgery. The primary end points were clinical response rates (cRR) and preoperative endocrine prognostic index (PEPI). The secondary end points were pathologic response and gene expression testing with EP test on collected tumor samples. The following results were obtained. 17 patients showed a clinical response of 50% or more, including 8 complete responses and 9 partial responses. There was significant reduction in area (P < 0.0001) and volume (P = 0.017) of the cancer. Pathologic complete response (pCR) was achieved in one patient; all cancers were downgraded after treatment. Ki67 (P = 0.044) and EP scores (P < 0.0001) were significantly reduced after treatment. Analysis of the relative gene expression levels showed that all proliferative genes, IL6ST and RBBP8 were decreased after palbociclib treatment. 6 patients with intermediate and three patients with high PEPI risk scores were found to have low EPclin scores. All patients with high PEPI relapse risk score had high EPclin score. In conclusion, effective clinical response was demonstrated by neoadjuvant letrozole in combination with palbociclib. Compared with PEPI, EPclin might be a better parameter to estimate prognosis after neoadjuvant therapy.
Search for other papers by Paula Fontes Asprino in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil
Search for other papers by Rudinei Diogo Marques Linck in
Google Scholar
PubMed
Search for other papers by Jônatas Cesar in
Google Scholar
PubMed
Search for other papers by Florêncio Porto Freitas in
Google Scholar
PubMed
Search for other papers by Fernanda Christtanini Koyama in
Google Scholar
PubMed
Search for other papers by Rachel Simões Pimenta Riechelmann in
Google Scholar
PubMed
Search for other papers by Frederico Perego Costa in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil
Search for other papers by Paulo Marcelo Gehm Hoff in
Google Scholar
PubMed
Search for other papers by Pedro Alexandre Favoretto Galante in
Google Scholar
PubMed
Search for other papers by Diogo Meyer in
Google Scholar
PubMed
Search for other papers by Anamaria Aranha Camargo in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil
Search for other papers by Jorge Sabbaga in
Google Scholar
PubMed
Search for other papers by Philipp Y Maximov in
Google Scholar
PubMed
Search for other papers by Balkees Abderrahman in
Google Scholar
PubMed
Search for other papers by Ramona F Curpan in
Google Scholar
PubMed
Search for other papers by Yousef M Hawsawi in
Google Scholar
PubMed
Search for other papers by Ping Fan in
Google Scholar
PubMed
Search for other papers by V Craig Jordan in
Google Scholar
PubMed
Prostate and breast cancer are the two cancers with the highest incidence in men and women, respectively. Here, we focus on the known biology of acquired resistance to antihormone therapy of prostate and breast cancer and compare laboratory and clinical similarities in the evolution of the disease. Laboratory studies and clinical observations in prostate and breast cancer demonstrate that cell selection pathways occur during acquired resistance to antihormonal therapy. Following sex steroid deprivation, both prostate and breast cancer models show an initial increased acquired sensitivity to the growth potential of sex steroids. Subsequently, prostate and breast cancer cells either become dependent upon the antihormone treatment or grow spontaneously in the absence of hormones. Paradoxically, the physiologic sex steroids now kill a proportion of selected, but vulnerable, resistant tumor cells. The sex steroid receptor complex triggers apoptosis. We draw parallels between acquired resistance in prostate and breast cancer to sex steroid deprivation. Clinical observations and patient trials confirm the veracity of the laboratory studies. We consider therapeutic strategies to increase response rates in clinical trials of metastatic disease that can subsequently be applied as a preemptive salvage adjuvant therapy. The goal of future advances is to enhance response rates and deploy a safe strategy earlier in the treatment plan to save lives. The introduction of a simple evidence-based enhanced adjuvant therapy as a global healthcare strategy has the potential to control recurrence, reduce hospitalization, reduce healthcare costs and maintain a healthier population that contributes to society.
Search for other papers by Takeshi Ujike in
Google Scholar
PubMed
Department of Therapeutic Urologic Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
Search for other papers by Motohide Uemura in
Google Scholar
PubMed
Search for other papers by Atsunari Kawashima in
Google Scholar
PubMed
Search for other papers by Akira Nagahara in
Google Scholar
PubMed
Search for other papers by Kazutoshi Fujita in
Google Scholar
PubMed
Search for other papers by Yasushi Miyagawa in
Google Scholar
PubMed
Search for other papers by Norio Nonomura in
Google Scholar
PubMed
Circulating levels of prostate-specific antigen (PSA) and testosterone are widely used for the detection of prostate cancer prior to prostate biopsy; however, both remain controversial. Effective screening strategies based on quantitative factors could help avoid unnecessary biopsies. Here, we sought to clarify the predictive value of free testosterone (FT) vs total testosterone (TT) in identifying patients likely to have positive biopsies. This study aims to develop a novel model for predicting positive prostate biopsy based on serum androgen levels. This study included 253 Japanese patients who underwent prostate biopsy at our institution. TT and FT, %FT (=FT/TT), age, PSA, prostate volume (PV) and PSA density (PSAD = PSA/PV) were assessed for association with prostate biopsy findings. The following results were obtained. Of 253 patients, 145 (57.3%) had positive biopsies. Compared to the negative biopsy group, the positive biopsy group demonstrated higher age, PSA and PSAD but lower PV, FT and %FT by univariate analysis. Multivariate logistic regression analysis indicated PSA, PSAD and %FT were independent predictors of cancer detection. We developed a predictive model based on PSAD and %FT, for which the area under the curve was significantly greater than that of PSA (0.82 vs 0.66), a well-known predictor. Applying this analysis to the subset of patients with PSA <10 ng/mL yielded similar results. We confirmed the utility of this model in another independent cohort of 88 patients. In conclusion, lower %FT predicted a positive prostate biopsy. We constructed a predictive model based on %FT and PSAD, which are easily obtained prior to biopsy.
Department of Oncology, Zhoushan Hospital, Zhoushan, China
Search for other papers by Hongqiang Wang in
Google Scholar
PubMed
Search for other papers by Rui Zhou in
Google Scholar
PubMed
Search for other papers by Li Sun in
Google Scholar
PubMed
Search for other papers by Jianling Xia in
Google Scholar
PubMed
Search for other papers by Xuchun Yang in
Google Scholar
PubMed
Search for other papers by Changqie Pan in
Google Scholar
PubMed
Search for other papers by Na Huang in
Google Scholar
PubMed
Search for other papers by Min Shi in
Google Scholar
PubMed
Search for other papers by Jianping Bin in
Google Scholar
PubMed
Search for other papers by Yulin Liao in
Google Scholar
PubMed
Search for other papers by Wangjun Liao in
Google Scholar
PubMed
Aerobic glycolysis plays an important role in cancer progression. New target genes regulating cancer aerobic glycolysis must be explored to improve patient prognosis. Mitochondrial topoisomerase I (TOP1MT) deficiency suppresses glucose oxidative metabolism but enhances glycolysis in normal cells. Here, we examined the role of TOP1MT in gastric cancer (GC) and attempted to determine the underlying mechanism. Using in vitro and in vivo experiments and analyzing the clinicopathological characteristics of patients with GC, we found that TOP1MT expression was lower in GC samples than in adjacent nonmalignant tissues. TOP1MT knockdown significantly promoted GC migration and invasion in vitro and in vivo. Importantly, TOP1MT silencing increased glucose consumption, lactate production, glucose transporter 1 expression and the epithelial-mesenchymal transition (EMT) in GC. Additionally, regulation of glucose metabolism induced by TOP1MT was significantly associated with lactate dehydrogenase A (LDHA) expression. A retrospective analysis of clinical data from 295 patients with GC demonstrated that low TOP1MT expression was associated with lymph node metastasis, recurrence and high mortality rates. TOP1MT deficiency enhanced glucose aerobic glycolysis by stimulating LDHA to promote GC progression.
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Emil Natchev in
Google Scholar
PubMed
Search for other papers by Luigi Maione in
Google Scholar
PubMed
Search for other papers by Karin Blijdorp in
Google Scholar
PubMed
Search for other papers by Mona Sahnoun-Fathallah in
Google Scholar
PubMed
Search for other papers by Renata Auriemma in
Google Scholar
PubMed
Search for other papers by Alpha M Diallo in
Google Scholar
PubMed
Search for other papers by Anna-Lena Hulting in
Google Scholar
PubMed
Search for other papers by Diego Ferone in
Google Scholar
PubMed
Search for other papers by Vaclav Hana Jr in
Google Scholar
PubMed
Search for other papers by Silvia Filipponi in
Google Scholar
PubMed
Search for other papers by Caroline Sievers in
Google Scholar
PubMed
Search for other papers by Claudia Nogueira in
Google Scholar
PubMed
Search for other papers by Carmen Fajardo-Montañana in
Google Scholar
PubMed
Search for other papers by Davide Carvalho in
Google Scholar
PubMed
Search for other papers by Vaclav Hana in
Google Scholar
PubMed
Search for other papers by Günter K Stalla in
Google Scholar
PubMed
Search for other papers by Marie-Lise Jaffrain-Réa in
Google Scholar
PubMed
Search for other papers by Brigitte Delemer in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Thierry Brue in
Google Scholar
PubMed
Search for other papers by Sebastian J C M M Neggers in
Google Scholar
PubMed
Search for other papers by Sabina Zacharieva in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion. While diagnostic and therapeutic methods have advanced, little information exists on trends in acromegaly characteristics over time. The Liège Acromegaly Survey (LAS) Database, a relational database, is designed to assess the profile of acromegaly patients at diagnosis and during long-term follow-up at multiple treatment centers. The following results were obtained at diagnosis. The study population consisted of 3173 acromegaly patients from ten countries; 54.5% were female. Males were significantly younger at diagnosis than females (43.5 vs 46.4 years; P < 0.001). The median delay from first symptoms to diagnosis was 2 years longer in females (P = 0.015). Ages at diagnosis and first symptoms increased significantly over time (P < 0.001). Tumors were larger in males than females (P < 0.001); tumor size and invasion were inversely related to patient age (P < 0.001). Random GH at diagnosis correlated with nadir GH levels during OGTT (P < 0.001). GH was inversely related to age in both sexes (P < 0.001). Diabetes mellitus was present in 27.5%, hypertension in 28.8%, sleep apnea syndrome in 25.5% and cardiac hypertrophy in 15.5%. Serious cardiovascular outcomes like stroke, heart failure and myocardial infarction were present in <5% at diagnosis. Erythrocyte levels were increased and correlated with IGF-1 values. Thyroid nodules were frequent (34.0%); 820 patients had colonoscopy at diagnosis and 13% had polyps. Osteoporosis was present at diagnosis in 12.3% and 0.6–4.4% had experienced a fracture. In conclusion, this study of >3100 patients is the largest international acromegaly database and shows clinically relevant trends in the characteristics of acromegaly at diagnosis.
Search for other papers by Catherine Zabkiewicz in
Google Scholar
PubMed
Search for other papers by Jeyna Resaul in
Google Scholar
PubMed
Search for other papers by Rachel Hargest in
Google Scholar
PubMed
Search for other papers by Wen Guo Jiang in
Google Scholar
PubMed
Search for other papers by Lin Ye in
Google Scholar
PubMed
Bone morphogenetic proteins (BMPs) belong to the TGF-β super family, and are essential for the regulation of foetal development, tissue differentiation and homeostasis and a multitude of cellular functions. Naturally, this has led to the exploration of aberrance in this highly regulated system as a key factor in tumourigenesis. Originally identified for their role in osteogenesis and bone turnover, attention has been turned to the potential role of BMPs in tumour metastases to, and progression within, the bone niche. This is particularly pertinent to breast cancer, which commonly metastasises to bone, and in which studies have revealed aberrations of both BMP expression and signalling, which correlate clinically with breast cancer progression. Ultimately a BMP profile could provide new prognostic disease markers. As the evidence suggests a role for BMPs in regulating breast tumour cellular function, in particular interactions with tumour stroma and the bone metastatic microenvironment, there may be novel therapeutic potential in targeting BMP signalling in breast cancer. This review provides an update on the current knowledge of BMP abnormalities and their implication in the development and progression of breast cancer, particularly in the disease-specific bone metastasis.
